Future savings from specialty pharmacies will come at pharma companies' expense.
Thomas Baker
Advertisement
Articles by Thomas Baker
Advertisement
Latest Updated Articles
Specialty Therapies Lose Special StatusPublished: September 1st 2004 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: 2026 J.P. Morgan Healthcare Conference Coverage
2
JP Morgan 2026: AbbVie Advances its Pipeline
3
JP Morgan 2026: Eli Lilly’s Continuing GLP-1 Success
4
JP Morgan 2026: Genmab Prioritizing Sustained Growth Over Next Decade
5